



# CANCER IN MANITOBA

## INCIDENCE AND MORTALITY

### 2005 Annual Statistical Report

EPIDEMIOLOGY AND CANCER REGISTRY

675 McDermot Avenue

Winnipeg, Manitoba Canada

R3E 0V9

Phone: (204) 787-2157

Fax: (204) 786-0628

Email: [registry@cancercare.mb.ca](mailto:registry@cancercare.mb.ca)

<http://www.cancercare.mb.ca>



## Table of Contents

<b>Introduction and staff</b>	1
<b>Place of diagnosis and death, residence at diagnosis and death</b>	3
<b>Incidence and mortality by age distribution</b>	4
<b>Buccal cavity and Pharynx</b>	5
Lip	5
Tongue; Major salivary gland	6
Floor of mouth; Gum and other mouth	7
Nasopharynx; Oropharynx	8
Hypopharynx; Other buccal cavity and pharynx	9
<b>Digestive system</b>	10
Liver; Gallbladder	11
Esophagus	12
Stomach	13
Small intestine; Anus	14
Colon (excluding rectum)	15
Rectum and rectosigmoid	16
Pancreas	17
Other digestive system	18
<b>Respiratory</b>	19
Lung and bronchus	20
Larynx; Other respiratory system	21
<b>Bones and joints</b>	22
<b>Soft tissue (including heart)</b>	22
<b>Skin</b>	23
Melanoma	24
Other skin and <i>in situ</i>	25
<b>Kaposi sarcoma</b>	25
<b>Breast</b>	26
Breast ( <i>in situ</i> )	26
Breast (invasive)	27
<b>Female genital system</b>	28
Other female genital system	28
Cervix ( <i>in situ</i> and invasive)	29
Corpus uteri; Uterus NOS	30
Ovary	31
<b>Male genital system</b>	32
Testis; Penis; Other male genital system	32
Prostate ( <i>in situ</i> and invasive)	33

<b>Urinary system</b>	34
Bladder ( <i>in situ</i> )	34
Bladder (invasive)	35
Kidney and renal pelvis	36
Ureter; Other urinary system	37
<b>Eye</b>	38
<b>Brain and Other nervous system</b>	38
Brain (invasive)	39
Brain (uncertain and unspecified)	39
Brain and nervous system (benign); Other nervous system	40
<b>Endocrine</b>	41
Other endocrine	41
Thyroid	42
<b>Lymphoma</b>	43
Hodgkin disease	43
Non-Hodgkin lymphoma	44
Multiple Myeloma	45
<b>Leukemia</b>	45
Acute lymphocytic leukemia; Chronic lymphocytic leukemia	46
Acute myeloid leukemia; Chronic myeloid leukemia	47
Other leukemia	48
<b>Other, ill-defined and unknown</b>	48
<b>Neoplasms – uncertain and unspecified</b>	49
<b>Other in situ</b>	49
<b>Appendix 1: Incidence by site 2005</b>	50
<b>Appendix 2: Mortality by site 2005</b>	52
<b>Appendix 3: Sites with more than 50 cases (by stage, % and frequency)</b>	54
<b>Appendix 4: ICD-O-3 codes</b>	57





## 2005 ANNUAL STATISTICAL REPORT

### THE MANITOBA CANCER REGISTRY

CancerCare Manitoba is legally mandated under the Public Health Act of Manitoba to collect, classify and maintain accurate comprehensive information on all cancer cases for the province of Manitoba. The Manitoba Cancer Registry is a population-based central cancer registry housed in the Department of Epidemiology and Cancer Registry.

Information sources include:

- Cytology and Pathology Departments in the Province of Manitoba
- Admission/Separation data from the provincial hospital abstracting system
- Vital Statistics deceased information from the provincial Vital Statistics Department
- Letters and “Report of Malignant Neoplasm Forms” from physicians and other health care providers
- Hospital health records
- Correspondence from other provincial and territorial cancer registries on Manitoba residents diagnosed and/or treated in their jurisdictions

#### **The Cancer Registry Data are utilized for:**

- Annual Statistical Reports
- Canadian Cancer Registry, North American Association of Central Cancer Registries and the International Association of Cancer Registries
- Education
- Health care planning and monitoring
- Surveillance and studies on the causes and prevention of cancer, cancer clusters, treatment patterns, outcomes and survival
- Patient care
- Quality assurance

#### **Requests for Information**

- We respect and protect the right to privacy of the patient and ensure the appropriate use of confidential health information.
- Requests for information for study and research purposes are processed through the Resource Impact Committee and relevant Ethics Boards for approval.
- The Provincial Personal Health Information Act (PHIA) and the Federal Personal Information Protection and Electronic Documents Act (PIPEDA) are complied with at all times.
- Disease related data for diagnostic clarification, treatment planning and previous cancer history can be provided by our Certified Cancer Registrars to assist the physician(s), pathologist(s) and other health care providers directly involved in the care of the patient.
- Statistical information is available for all published annual report data upon request.

#### **In 2005, the Cancer Registry staff participated in and/or performed the following:**

---

64	New studies	16	Quality Assurance reviews and edits
11	On-going studies	2	Manitoba Health duplicate match reviews
21	Statistical requests (phone calls/fax requests)	72	Cancer Registry Monthly Edits (six each month)
889	Provision of disease related data for diagnostic clarification and treatment planning including Estrogen and Progesterone report assay results	1	Inter-provincial exchange of information

The Manitoba Cancer Registry continues to be the Estrogen Progesterone (ER/PR) report assay registry for the Province of Manitoba.

**ANNUAL REPORT GUIDE:**

**INCIDENCE DATA:** Cancer cases diagnosed in the 2005 calendar year. Incidence is also provided by stage of disease at diagnosis.

**MORTALITY DATA:** Manitobans who died of cancer in the 2005 calendar year but not necessarily diagnosed in that year. This information has been provided to us from the Vital Statistics Department, Province of Manitoba. The totals in the summary on page 3 include all cancer deaths occurring in the Province.

**POPULATION DATA:** Data is based on the Manitoba Health population estimates for Manitoba.

**RATES:** Rates are calculated by dividing the number of cases (incidence and mortality) identified by the number of individuals in that specific category (age/sex/region) multiplied by 100,000.

**CANCER INCIDENCE AND MORTALITY:** Tables of incidence and mortality are categorized in this report according to the International Classification of Diseases for Oncology Third edition (ICD-O-3<sup>rd</sup> ed.).

**NOTE:** All statistics in the body of the annual report include Manitoba residents only.

**EPIDEMIOLOGY and CANCER REGISTRY 2005/2006**

**Cancer Registry Staff:**

**Managers:** Jeri Kostyra, CTR  
Gail Noonan, HRT

**Cancer Registrars:**

Elena Avila, HIT  
Douglas Buffie, HIT  
Jennifer Cadger, HIT  
Angela Deneka, HIT  
Sheila Fukumura, HIT  
Terri-Lee Handel, HIT  
Coreen Hildebrand, HRT, CTR (Sr. Quality Control Technician)  
Jo-Anne Janzen, HRT, CTR (Sr. Cancer Registrar)  
Shannon Kornelsen, HIT  
Loriann Love, HRT  
Grace Pontanares, HIT  
Kim Shore, HRT

**Clerical Support:**

Alfreda Cookson (Senior Clerical)  
Judy Perry (Senior Clerical)  
Sharon Lawrence  
Cherry Pacheco

**Epidemiology Staff:**

**Manager:** Donna Turner, PhD

**Epidemiologists:**

Alain Demers, PhD  
Jane Griffith, PhD  
Erich Kliewer, PhD

**Programmer Analysts:**

Wendy Fonseca-Holt, BSc, BCScH  
Grace Musto, BSc  
Xiaoyun Sun, BSc  
Lin Xue, BSc

**Health Outcomes Analysts:**

Katherine Fradette, BSc  
Karen Hildebrand, MSc  
Zoann Nugent, PhD

**Project Manager:**

Cheryl Clague

**Administrative Assistant:**

Karen Goertzen



Place of diagnosis	Male	Female	Total
Health Sciences Centre	917	786	1703
St. Boniface General Hospital	431	602	1033
Other Hospitals in Winnipeg	904	773	1677
Other Hospitals in Manitoba	868	1328	2196
Hospitals Outside Manitoba	87	104	191
Doctors and Clinics in Winnipeg	898	801	1699
Doctors and Clinics in Manitoba	176	158	334
<b>Total</b>	<b>4281</b>	<b>4552</b>	<b>8833</b>

## MORTALITY

Place of death	Male	Female	Total
Hospitals – Winnipeg	689	661	1350
Hospitals – Outside Winnipeg	465	356	821
Nursing Homes	78	135	213
Other – Winnipeg	82	71	153
Other – Outside Winnipeg	72	42	114
<b>Total</b>	<b>1386</b>	<b>1265</b>	<b>2651</b>

## INCIDENCE

Residence at diagnosis	Male	Female	Total
Winnipeg	2270	2600	4870
Manitoba–Outside Winnipeg	1804	1763	3567
Non–Manitoba Residence	207	189	396
<b>Total</b>	<b>4281</b>	<b>4552</b>	<b>8833</b>

## MORTALITY

Residence at death	Male	Female	Total
Greater Winnipeg	728	764	1492
Manitoba – Outside Greater Winnipeg	639	491	1130
Residence Not Stated	19	10	29
<b>Total</b>	<b>1386</b>	<b>1265</b>	<b>2651</b>

**AGE DISTRIBUTION 2005**  
**(ALL SITES/INVASIVE & *IN SITU*)**

**INCIDENCE**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-04	11	30.23	11	31.66	22	30.93
05-09	5	12.65	2	5.34	7	9.09
10-14	3	6.86	6	14.32	9	10.51
15-19	8	18.34	23	55.22	31	36.36
20-24	17	41.66	54	135.45	71	88.02
25-29	20	52.76	76	199.84	96	126.43
30-34	37	96.39	73	189.89	110	143.17
35-39	43	108.38	108	272.82	151	190.51
40-44	90	191.75	183	390.33	273	290.98
45-49	151	330.17	280	622.21	431	475.01
50-54	254	629.16	348	851.54	602	741.03
55-59	396	1137.44	396	1120.38	792	1128.85
60-64	431	1669.18	414	1575.52	845	1621.94
65-69	547	2747.50	428	2000.00	975	2360.26
70-74	606	3518.96	438	2240.07	1044	2841.28
75-79	637	4569.58	532	2875.99	1169	3603.80
80+	818	4823.11	991	3095.13	1809	3693.50
<b>Total</b>	<b>4074</b>	<b>700.31</b>	<b>4363</b>	<b>730.18</b>	<b>8437</b>	<b>715.44</b>

**MORTALITY**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-04	1	2.75	0	0.00	1	1.41
05-09	2	5.06	2	5.34	4	5.20
10-14	2	4.57	0	0.00	2	2.34
15-19	1	2.29	0	0.00	1	1.17
20-24	2	4.90	2	5.02	4	4.96
25-29	0	0.00	3	7.89	3	3.95
30-34	0	0.00	2	5.20	2	2.60
35-39	5	12.60	12	30.31	17	21.45
40-44	11	23.44	24	51.19	35	37.31
45-49	35	76.53	41	91.11	76	83.76
50-54	57	141.19	58	141.92	115	141.56
55-59	83	238.40	84	237.66	167	238.03
60-64	98	379.54	102	388.17	200	383.89
65-69	156	783.57	127	593.46	283	685.08
70-74	205	1190.41	156	797.83	361	981.67
75-79	261	1872.31	196	1059.57	457	1408.84
80+	448	2641.51	446	1392.97	894	1825.31
<b>Total</b>	<b>1367</b>	<b>234.98</b>	<b>1255</b>	<b>210.03</b>	<b>2622</b>	<b>222.34</b>

**BUCCAL CAVITY AND PHARYNX (C00:C14)****INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	3	3.84	2	2.56	5	3.20
40-49	12	12.95	2	2.18	14	7.59
50-59	23	30.59	6	7.87	29	19.15
60-69	20	43.73	11	23.07	31	33.19
70-79	23	73.81	15	39.42	38	54.90
80+	10	58.96	13	40.60	23	46.96
<b>Total</b>	<b>92</b>	<b>15.81</b>	<b>49</b>	<b>8.20</b>	<b>141</b>	<b>11.96</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	3	3.24	0	0.00	3	1.63
50-59	5	6.65	0	0.00	5	3.30
60-69	2	4.37	3	6.29	5	5.35
70-79	4	12.84	4	10.51	8	11.56
80+	5	29.48	4	12.49	9	18.38
<b>Total</b>	<b>19</b>	<b>3.27</b>	<b>11</b>	<b>1.84</b>	<b>30</b>	<b>2.54</b>

**LIP****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	1	1.28	0	0.00	1	0.64
40-49	1	1.08	1	1.09	2	1.08
50-59	6	7.98	0	0.00	6	3.96
60-69	6	13.12	2	4.19	8	8.56
70-79	12	38.51	3	7.88	15	21.67
80+	6	35.38	5	15.62	11	22.46
<b>Total</b>	<b>33</b>	<b>5.67</b>	<b>11</b>	<b>1.84</b>	<b>44</b>	<b>3.73</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>

**TONGUE****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	2	2.56	3	1.92
40-49	4	4.32	1	1.09	5	2.71
50-59	6	7.98	4	5.25	10	6.61
60-69	5	10.93	4	8.39	9	9.64
70-79	4	12.84	4	10.51	8	11.56
80+	0	0.00	2	6.25	2	4.08
<b>Total</b>	<b>20</b>	<b>3.44</b>	<b>17</b>	<b>2.85</b>	<b>37</b>	<b>3.14</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	1	1.33	0	0.00	1	0.66
60-69	0	0.00	1	2.10	1	1.07
70-79	1	3.21	2	5.26	3	4.33
80+	2	11.79	2	6.25	4	8.17
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>5</b>	<b>0.84</b>	<b>10</b>	<b>0.85</b>

**MAJOR SALIVARY GLAND****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.16	0	0.00	2	1.08
50-59	1	1.33	0	0.00	1	0.66
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.21	2	5.26	3	4.33
80+	0	0.00	1	3.12	1	2.04
<b>Total</b>	<b>4</b>	<b>0.69</b>	<b>3</b>	<b>0.50</b>	<b>7</b>	<b>0.59</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.21	0	0.00	1	1.44
80+	2	11.79	1	3.12	3	6.13
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>1</b>	<b>0.17</b>	<b>4</b>	<b>0.34</b>

**FLOOR OF MOUTH****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	1	1.33	0	0.00	1	0.66
60-69	2	4.37	0	0.00	2	2.14
70-79	1	3.21	1	2.63	2	2.89
80+	0	0.00	1	3.12	1	2.04
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>2</b>	<b>0.33</b>	<b>7</b>	<b>0.59</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>

**GUM AND OTHER MOUTH****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	3	3.99	1	1.31	4	2.64
60-69	0	0.00	2	4.19	2	2.14
70-79	2	6.42	3	7.88	5	7.22
80+	0	0.00	4	12.49	4	8.17
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>10</b>	<b>1.67</b>	<b>15</b>	<b>1.27</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	0	0.00	1	0.66
60-69	1	2.19	0	0.00	1	1.07
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	1	3.12	1	2.04
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>2</b>	<b>0.33</b>	<b>4</b>	<b>0.34</b>

**NASOPHARYNX****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	0	0.00	1	0.64
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	0	0.00	1	0.66
60-69	0	0.00	1	2.10	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	2	11.79	0	0.00	2	4.08
<b>Total</b>	<b>4</b>	<b>0.69</b>	<b>1</b>	<b>0.17</b>	<b>5</b>	<b>0.42</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.19	0	0.00	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>0</b>	<b>0.00</b>	<b>2</b>	<b>0.17</b>

**OROPHARYNX****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	1	1.33	0	0.00	1	0.66
60-69	2	4.37	1	2.10	3	3.21
70-79	1	3.21	0	0.00	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>1</b>	<b>0.17</b>	<b>6</b>	<b>0.51</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	1	2.10	1	1.07
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>2</b>	<b>0.33</b>	<b>3</b>	<b>0.25</b>

HYPOPHARYNX

## INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	1	1.33	0	0.00	1	0.66
60-69	4	8.75	1	2.10	5	5.35
70-79	0	0.00	0	0.00	0	0.00
80+	1	5.90	0	0.00	1	2.04
<b>Total</b>	<b>7</b>	<b>1.20</b>	<b>1</b>	<b>0.17</b>	<b>8</b>	<b>0.68</b>

## MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	1	5.90	0	0.00	1	2.04
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.08</b>

OTHER BUCCAL CAVITY AND PHARYNX

## INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.16	0	0.00	2	1.08
50-59	3	3.99	1	1.31	4	2.64
60-69	1	2.19	0	0.00	1	1.07
70-79	2	6.42	2	5.26	4	5.78
80+	1	5.90	0	0.00	1	2.04
<b>Total</b>	<b>9</b>	<b>1.55</b>	<b>3</b>	<b>0.50</b>	<b>12</b>	<b>1.02</b>

## MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	3	3.99	0	0.00	3	1.98
60-69	0	0.00	1	2.10	1	1.07
70-79	2	6.42	0	0.00	2	2.89
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>1</b>	<b>0.17</b>	<b>6</b>	<b>0.51</b>

**DIGESTIVE SYSTEM (C15:C26)****INCIDENCE - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	2	0.83	1	0.43	3	0.63
30-39	15	19.22	10	12.82	25	16.02
40-49	37	39.93	40	43.53	77	41.72
50-59	120	159.60	61	80.04	181	119.55
60-69	144	314.89	101	211.84	245	262.29
70-79	194	622.57	141	370.56	335	484.02
80+	166	978.77	185	577.80	351	716.65
<b>Total</b>	<b>678</b>	<b>116.55</b>	<b>539</b>	<b>90.21</b>	<b>1217</b>	<b>103.20</b>

**MORTALITY - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	3	3.84	2	2.56	5	3.20
40-49	16	17.27	13	14.15	29	15.71
50-59	48	63.84	28	36.74	76	50.20
60-69	68	148.70	54	113.26	122	130.61
70-79	125	401.14	76	199.73	201	290.41
80+	103	607.31	124	387.28	227	463.47
<b>Total</b>	<b>363</b>	<b>62.40</b>	<b>297</b>	<b>49.71</b>	<b>660</b>	<b>55.97</b>



**LIVER****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	1	1.28	1	0.64
40-49	2	2.16	1	1.09	3	1.63
50-59	7	9.31	0	0.00	7	4.62
60-69	8	17.49	4	8.39	12	12.85
70-79	9	28.88	4	10.51	13	18.78
80+	5	29.48	4	12.49	9	18.38
<b>Total</b>	<b>31</b>	<b>5.33</b>	<b>14</b>	<b>2.34</b>	<b>45</b>	<b>3.82</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	1	1.09	2	1.08
50-59	5	6.65	2	2.62	7	4.62
60-69	6	13.12	2	4.19	8	8.56
70-79	9	28.88	0	0.00	9	13.00
80+	6	35.38	3	9.37	9	18.38
<b>Total</b>	<b>27</b>	<b>4.64</b>	<b>8</b>	<b>1.34</b>	<b>35</b>	<b>2.97</b>

**GALLBLADDER****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	2	2.18	2	1.08
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.19	2	4.19	3	3.21
70-79	3	9.63	5	13.14	8	11.56
80+	3	17.69	3	9.37	6	12.25
<b>Total</b>	<b>7</b>	<b>1.20</b>	<b>12</b>	<b>2.01</b>	<b>19</b>	<b>1.61</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	2	2.18	2	1.08
50-59	1	1.33	2	2.62	3	1.98
60-69	1	2.19	3	6.29	4	4.28
70-79	2	6.42	2	5.26	4	5.78
80+	3	17.69	2	6.25	5	10.21
<b>Total</b>	<b>7</b>	<b>1.20</b>	<b>11</b>	<b>1.84</b>	<b>18</b>	<b>1.53</b>


**ESOPHAGUS**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	4	4.32	0	0.00	4	2.17
50-59	6	7.98	1	1.31	7	4.62
60-69	11	24.05	6	12.58	17	18.20
70-79	15	48.14	4	10.51	19	27.45
80+	5	29.48	5	15.62	10	20.42
<b>Total</b>	<b>41</b>	<b>7.05</b>	<b>16</b>	<b>2.68</b>	<b>57</b>	<b>4.83</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	5	5.40	0	0.00	5	2.71
50-59	8	10.64	1	1.31	9	5.94
60-69	14	30.61	3	6.29	17	18.20
70-79	16	51.35	5	13.14	21	30.34
80+	9	53.07	10	31.23	19	38.79
<b>Total</b>	<b>52</b>	<b>8.94</b>	<b>19</b>	<b>3.18</b>	<b>71</b>	<b>6.02</b>




\*See Appendix 3 for frequency of incidence for each site

**STOMACH****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	3	3.84	1	1.28	4	2.56
40-49	2	2.16	3	3.26	5	2.71
50-59	10	13.30	7	9.18	17	11.23
60-69	18	39.36	12	25.17	30	32.12
70-79	20	64.18	11	28.91	31	44.79
80+	21	123.82	13	40.60	34	69.42
<b>Total</b>	<b>74</b>	<b>12.72</b>	<b>47</b>	<b>7.87</b>	<b>121</b>	<b>10.26</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	2	2.56	2	1.28
40-49	2	2.16	4	4.35	6	3.25
50-59	4	5.32	1	1.31	5	3.30
60-69	6	13.12	5	10.49	11	11.78
70-79	9	28.88	6	15.77	15	21.67
80+	19	112.03	16	49.97	35	71.46
<b>Total</b>	<b>40</b>	<b>6.88</b>	<b>34</b>	<b>5.69</b>	<b>74</b>	<b>6.28</b>



\*See Appendix 3 for frequency of incidence for each site

**SMALL INTESTINE****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	1	1.28	2	1.28
40-49	0	0.00	1	1.09	1	0.54
50-59	6	7.98	1	1.31	7	4.62
60-69	5	10.93	2	4.19	7	7.49
70-79	4	12.84	4	10.51	8	11.56
80+	5	29.48	6	18.74	11	22.46
<b>Total</b>	<b>21</b>	<b>3.61</b>	<b>15</b>	<b>2.51</b>	<b>36</b>	<b>3.05</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	2	4.37	0	0.00	2	2.14
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	2	6.25	2	4.08
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>3</b>	<b>0.50</b>	<b>5</b>	<b>0.42</b>

**ANUS****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	1	1.28	2	1.28
40-49	1	1.08	2	2.18	3	1.63
50-59	1	1.33	2	2.62	3	1.98
60-69	3	6.56	2	4.19	5	5.35
70-79	0	0.00	2	5.26	2	2.89
80+	2	11.79	1	3.12	3	6.13
<b>Total</b>	<b>8</b>	<b>1.38</b>	<b>10</b>	<b>1.67</b>	<b>18</b>	<b>1.53</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	0	0.00	1	1.31	1	0.66
60-69	1	2.19	0	0.00	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>2</b>	<b>0.33</b>	<b>3</b>	<b>0.25</b>


**COLON (EXCLUDING RECTUM)****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	0	0.00	2	0.42
30-39	5	6.41	3	3.84	8	5.13
40-49	10	10.79	14	15.24	24	13.00
50-59	45	59.85	33	43.30	78	51.52
60-69	40	87.47	39	81.80	79	84.58
70-79	66	211.80	64	168.20	130	187.83
80+	78	459.91	100	312.32	178	363.43
<b>Total</b>	<b>246</b>	<b>42.29</b>	<b>253</b>	<b>42.34</b>	<b>499</b>	<b>42.31</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	0	0.00	1	0.64
40-49	4	4.32	2	2.18	6	3.25
50-59	20	26.60	9	11.81	29	19.15
60-69	17	37.17	22	46.14	39	41.75
70-79	40	128.37	34	89.35	74	106.92
80+	34	200.47	56	174.90	90	183.76
<b>Total</b>	<b>116</b>	<b>19.94</b>	<b>123</b>	<b>20.58</b>	<b>239</b>	<b>20.27</b>

**Incidence of Colon Cancer (excluding Rectum)  
by Stage\***



\*See Appendix 3 for frequency of incidence for each site


**RECTUM AND RECTOSIGMOID**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	2	2.56	2	2.56	4	2.56
40-49	11	11.87	13	14.15	24	13.00
50-59	32	42.56	6	7.87	38	25.10
60-69	33	72.16	23	48.24	56	59.95
70-79	48	154.04	24	63.07	72	104.03
80+	27	159.20	26	81.20	53	108.21
<b>Total</b>	<b>153</b>	<b>26.30</b>	<b>94</b>	<b>15.73</b>	<b>247</b>	<b>20.95</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	0	0.00	1	0.64
40-49	1	1.08	1	1.09	2	1.08
50-59	3	3.99	2	2.62	5	3.30
60-69	6	13.12	6	12.58	12	12.85
70-79	16	51.35	5	13.14	21	30.34
80+	15	88.44	13	40.60	28	57.17
<b>Total</b>	<b>42</b>	<b>7.22</b>	<b>27</b>	<b>4.52</b>	<b>69</b>	<b>5.85</b>



\*See Appendix 3 for frequency of incidence for each site


**PANCREAS****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	1	1.28	1	1.28	2	1.28
40-49	3	3.24	3	3.26	6	3.25
50-59	11	14.63	9	11.81	20	13.21
60-69	14	30.61	6	12.58	20	21.41
70-79	19	60.97	17	44.68	36	52.01
80+	15	88.44	20	62.46	35	71.46
<b>Total</b>	<b>63</b>	<b>10.83</b>	<b>57</b>	<b>9.54</b>	<b>120</b>	<b>10.18</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	2	2.16	1	1.09	3	1.63
50-59	7	9.31	9	11.81	16	10.57
60-69	12	26.24	10	20.97	22	23.55
70-79	29	93.07	18	47.30	47	67.91
80+	16	94.34	16	49.97	32	65.34
<b>Total</b>	<b>66</b>	<b>11.35</b>	<b>54</b>	<b>9.04</b>	<b>120</b>	<b>10.18</b>

**Incidence of Pancreatic Cancer**  
**by Stage\***



\*See Appendix 3 for frequency of incidence for each site

**OTHER DIGESTIVE SYSTEM****INCIDENCE**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	2	2.56	0	0.00	2	1.28
40-49	4	4.32	1	1.09	5	2.71
50-59	2	2.66	2	2.62	4	2.64
60-69	11	24.05	5	10.49	16	17.13
70-79	10	32.09	6	15.77	16	23.12
80+	5	29.48	7	21.86	12	24.50
<b>Total</b>	<b>34</b>	<b>5.84</b>	<b>21</b>	<b>3.51</b>	<b>55</b>	<b>4.66</b>

**MORTALITY**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	0	0.00	1	0.64
40-49	1	1.08	1	1.09	2	1.08
50-59	0	0.00	1	1.31	1	0.66
60-69	3	6.56	3	6.29	6	6.42
70-79	4	12.84	5	13.14	9	13.00
80+	1	5.90	6	18.74	7	14.29
<b>Total</b>	<b>10</b>	<b>1.72</b>	<b>16</b>	<b>2.68</b>	<b>26</b>	<b>2.20</b>



**RESPIRATORY SYSTEM (C30:39)****INCIDENCE - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	1	0.43	1	0.21
30-39	2	2.56	1	1.28	3	1.92
40-49	14	15.11	15	16.32	29	15.71
50-59	71	94.43	65	85.29	136	89.83
60-69	123	268.97	102	213.94	225	240.88
70-79	186	596.90	158	415.23	344	497.02
80+	85	501.18	83	259.23	168	343.01
<b>Total</b>	<b>481</b>	<b>82.68</b>	<b>425</b>	<b>71.13</b>	<b>906</b>	<b>76.83</b>

**MORTALITY - TOTAL**

<b>Age</b>	<b>Male</b>	<b>Rate</b>	<b>Female</b>	<b>Rate</b>	<b>Total</b>	<b>Rate</b>
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	2	2.56	2	1.28
40-49	7	7.55	12	13.06	19	10.29
50-59	48	63.84	38	49.86	86	56.80
60-69	88	192.43	62	130.04	150	160.59
70-79	134	430.02	109	286.46	243	351.10
80+	101	595.52	79	246.74	180	367.51
<b>Total</b>	<b>378</b>	<b>64.98</b>	<b>302</b>	<b>50.54</b>	<b>680</b>	<b>57.66</b>


**LUNG AND BRONCHUS**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	1	1.28	2	1.28
40-49	14	15.11	14	15.24	28	15.17
50-59	66	87.78	63	82.66	129	85.21
60-69	118	258.04	100	209.74	218	233.39
70-79	173	555.18	154	404.72	327	472.46
80+	74	436.32	82	256.11	156	318.51
<b>Total</b>	<b>446</b>	<b>76.67</b>	<b>414</b>	<b>69.29</b>	<b>860</b>	<b>72.93</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	2	2.56	2	1.28
40-49	6	6.47	12	13.06	18	9.75
50-59	47	62.51	36	47.24	83	54.82
60-69	84	183.69	61	127.94	145	155.23
70-79	130	417.19	107	281.20	237	342.43
80+	100	589.62	78	243.61	178	363.43
<b>Total</b>	<b>367</b>	<b>63.09</b>	<b>296</b>	<b>49.54</b>	<b>663</b>	<b>56.22</b>



\*See Appendix 3 for frequency of incidence for each site

LARYNX

## INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	3	3.99	1	1.31	4	2.64
60-69	4	8.75	2	4.19	6	6.42
70-79	9	28.88	2	5.26	11	15.89
80+	3	17.69	0	0.00	3	6.13
<b>Total</b>	<b>19</b>	<b>3.27</b>	<b>5</b>	<b>0.84</b>	<b>24</b>	<b>2.04</b>

## MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	0	0.00	1	1.31	1	0.66
60-69	4	8.75	1	2.10	5	5.35
70-79	3	9.63	2	5.26	5	7.22
80+	1	5.90	0	0.00	1	2.04
<b>Total</b>	<b>9</b>	<b>1.55</b>	<b>4</b>	<b>0.67</b>	<b>13</b>	<b>1.10</b>

OTHER RESPIRATORY SYSTEM

## INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	1	1.28	0	0.00	1	0.64
40-49	0	0.00	1	1.09	1	0.54
50-59	2	2.66	1	1.31	3	1.98
60-69	1	2.19	0	0.00	1	1.07
70-79	4	12.84	2	5.26	6	8.67
80+	8	47.17	1	3.12	9	18.38
<b>Total</b>	<b>16</b>	<b>2.75</b>	<b>6</b>	<b>1.00</b>	<b>22</b>	<b>1.87</b>

## MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	1	1.31	2	1.32
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.21	0	0.00	1	1.44
80+	1	5.90	1	3.12	2	4.08
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>2</b>	<b>0.33</b>	<b>5</b>	<b>0.42</b>

**BONES AND JOINTS (C40:41)****INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	3	1.24	0	0.00	3	0.63
30-39	0	0.00	1	1.28	1	0.64
40-49	2	2.16	0	0.00	2	1.08
50-59	1	1.33	0	0.00	1	0.66
60-69	2	4.37	0	0.00	2	2.14
70-79	1	3.21	1	2.63	2	2.89
80+	1	5.90	0	0.00	1	2.04
<b>Total</b>	<b>10</b>	<b>1.72</b>	<b>2</b>	<b>0.33</b>	<b>12</b>	<b>1.02</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	1	2.63	1	1.44
80+	2	11.79	0	0.00	2	4.08
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>2</b>	<b>0.33</b>	<b>5</b>	<b>0.42</b>

**SOFT TISSUE (INCLUDING HEART)****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	3	1.28	5	1.05
30-39	1	1.28	0	0.00	1	0.64
40-49	0	0.00	3	3.26	3	1.63
50-59	4	5.32	2	2.62	6	3.96
60-69	4	8.75	2	4.19	6	6.42
70-79	4	12.84	3	7.88	7	10.11
80+	2	11.79	2	6.25	4	8.17
<b>Total</b>	<b>17</b>	<b>2.92</b>	<b>15</b>	<b>2.51</b>	<b>32</b>	<b>2.71</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	3	3.26	3	1.63
50-59	3	3.99	0	0.00	3	1.98
60-69	8	17.49	2	4.19	10	10.71
70-79	6	19.25	4	10.51	10	14.45
80+	6	35.38	2	6.25	8	16.33
<b>Total</b>	<b>24</b>	<b>4.13</b>	<b>11</b>	<b>1.84</b>	<b>35</b>	<b>2.97</b>

**SKIN - MELANOMA & NON-MELANOMA (C44)****INCIDENCE - TOTAL (INCLUDES *IN SITU*)**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	4	1.65	12	5.14	16	3.36
30-39	23	29.46	43	55.11	66	42.28
40-49	94	101.43	110	119.71	204	110.54
50-59	200	266.01	163	213.88	363	239.77
60-69	242	529.19	180	377.54	422	451.79
70-79	337	1081.48	244	641.24	581	839.45
80+	267	1574.29	303	946.34	570	1163.79
<b>Total</b>	<b>1167</b>	<b>200.60</b>	<b>1055</b>	<b>176.56</b>	<b>2222</b>	<b>188.42</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	1	1.28	2	1.28
40-49	0	0.00	4	4.35	4	2.17
50-59	2	2.66	1	1.31	3	1.98
60-69	3	6.56	1	2.10	4	4.28
70-79	0	0.00	1	2.63	1	1.44
80+	3	17.69	6	18.74	9	18.38
<b>Total</b>	<b>9</b>	<b>1.55</b>	<b>14</b>	<b>2.34</b>	<b>23</b>	<b>1.95</b>


**MELANOMA OF THE SKIN**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	5	2.14	7	1.47
30-39	3	3.84	7	8.97	10	6.41
40-49	15	16.19	16	17.41	31	16.80
50-59	15	19.95	15	19.68	30	19.82
60-69	15	32.80	13	27.27	28	29.98
70-79	13	41.72	9	23.65	22	31.79
80+	11	64.86	5	15.62	16	32.67
<b>Total</b>	<b>74</b>	<b>12.72</b>	<b>70</b>	<b>11.71</b>	<b>144</b>	<b>12.21</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	1	1.28	2	1.28
40-49	0	0.00	4	4.35	4	2.17
50-59	2	2.66	0	0.00	2	1.32
60-69	3	6.56	1	2.10	4	4.28
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	4	12.49	4	8.17
<b>Total</b>	<b>6</b>	<b>1.03</b>	<b>11</b>	<b>1.84</b>	<b>17</b>	<b>1.44</b>



\*See Appendix 3 for frequency of incidence for each site

**OTHER SKIN AND *IN SITU*<sup>1</sup>****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	7	3.00	9	1.89
30-39	20	25.62	36	46.14	56	35.88
40-49	79	85.25	94	102.30	173	93.74
50-59	185	246.06	148	194.20	333	219.95
60-69	227	496.39	167	350.27	394	421.81
70-79	324	1039.76	235	617.59	559	807.66
80+	256	1509.43	298	930.73	554	1131.12
<b>Total</b>	<b>1093</b>	<b>187.88</b>	<b>985</b>	<b>164.85</b>	<b>2078</b>	<b>176.21</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.31	1	0.66
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	3	17.69	2	6.25	5	10.21
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>3</b>	<b>0.50</b>	<b>6</b>	<b>0.51</b>

<sup>1</sup>Includes melanoma *in situ***KAPOSI SARCOMA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	1	2.10	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.08</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.17</b>	<b>1</b>	<b>0.08</b>

**BREAST - INVASIVE AND *IN SITU* (C500:C509)****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	22	28.19	22	14.09
40-49	0	0.00	132	143.66	132	71.52
50-59	0	0.00	235	308.35	235	155.22
60-69	1	2.19	217	455.15	218	233.39
70-79	1	3.21	146	383.70	147	212.39
80+	1	5.90	157	490.35	158	322.59
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>910</b>	<b>152.29</b>	<b>913</b>	<b>77.42</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	4	5.13	4	2.56
40-49	1	1.08	13	14.15	14	7.59
50-59	0	0.00	29	38.05	29	19.15
60-69	0	0.00	30	62.92	30	32.12
70-79	0	0.00	37	97.24	37	53.46
80+	2	11.79	73	228.00	75	153.13
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>186</b>	<b>31.13</b>	<b>189</b>	<b>16.03</b>

**BREAST - *IN SITU*****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	2	2.56	2	1.28
40-49	0	0.00	17	18.50	17	9.21
50-59	0	0.00	41	53.80	41	27.08
60-69	1	2.19	36	75.51	37	39.61
70-79	0	0.00	15	39.42	15	21.67
80+	0	0.00	14	43.73	14	28.58
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>125</b>	<b>20.92</b>	<b>126</b>	<b>10.68</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>




**BREAST - INVASIVE****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	20	25.63	20	12.81
40-49	0	0.00	115	125.16	115	62.31
50-59	0	0.00	194	254.55	194	128.14
60-69	0	0.00	181	379.64	181	193.78
70-79	1	3.21	131	344.27	132	190.72
80+	1	5.90	143	446.62	144	294.01
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>785</b>	<b>131.38</b>	<b>787</b>	<b>66.74</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	4	5.13	4	2.56
40-49	1	1.08	13	14.15	14	7.59
50-59	0	0.00	29	38.05	29	19.15
60-69	0	0.00	30	62.92	30	32.12
70-79	0	0.00	37	97.24	37	53.46
80+	2	11.79	73	228.00	75	153.13
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>186</b>	<b>31.13</b>	<b>189</b>	<b>16.03</b>



\*See Appendix 3 for frequency of incidence for each site

**FEMALE GENITAL SYSTEM (C51:C58)****INCIDENCE - TOTAL**

Age	Female	Rate
00-29	110	47.08
30-39	74	94.84
40-49	88	95.77
50-59	97	127.28
60-69	77	161.50
70-79	66	173.45
80+	32	99.94
<b>Total</b>	<b>544</b>	<b>91.04</b>

**MORTALITY - TOTAL**

Age	Female	Rate
00-29	1	0.43
30-39	4	5.13
40-49	4	4.35
50-59	16	20.99
60-69	28	58.73
70-79	27	70.96
80+	19	59.34
<b>Total</b>	<b>99</b>	<b>16.57</b>

**OTHER FEMALE GENITAL SYSTEM****INCIDENCE**

Age	Female	Rate
00-29	1	0.43
30-39	2	2.56
40-49	6	6.53
50-59	5	6.56
60-69	4	8.39
70-79	6	15.77
80+	2	6.25
<b>Total</b>	<b>26</b>	<b>4.35</b>

**MORTALITY**

Age	Female	Rate
00-29	1	0.43
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	4	8.39
70-79	3	7.88
80+	2	6.25
<b>Total</b>	<b>10</b>	<b>1.67</b>

**CERVIX - IN SITU**

**INCIDENCE**

Age	Female	Rate
00-29	100	42.80
30-39	57	73.05
40-49	37	40.27
50-59	5	6.56
60-69	7	14.68
70-79	2	5.26
80+	0	0.00
<b>Total</b>	<b>208</b>	<b>34.81</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>


**CERVIX - INVASIVE**

**INCIDENCE**

Age	Female	Rate
00-29	7	3.00
30-39	9	11.53
40-49	13	14.15
50-59	12	15.75
60-69	7	14.68
70-79	7	18.40
80+	3	9.37
<b>Total</b>	<b>58</b>	<b>9.71</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	4	5.13
40-49	1	1.09
50-59	2	2.62
60-69	3	6.29
70-79	3	7.88
80+	1	3.12
<b>Total</b>	<b>14</b>	<b>2.34</b>



\*See Appendix 3 for frequency of incidence for each site


**CORPUS UTERI**

**INCIDENCE**

Age	Female	Rate
00-29	1	0.43
30-39	2	2.56
40-49	21	22.85
50-59	54	70.85
60-69	38	79.70
70-79	34	89.35
80+	13	40.60
<b>Total</b>	<b>163</b>	<b>27.28</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	1	1.31
60-69	2	4.19
70-79	4	10.51
80+	4	12.49
<b>Total</b>	<b>11</b>	<b>1.84</b>



\*See Appendix 3 for frequency of incidence for each site

**UTERUS, NOS**

**INCIDENCE**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	1	2.10
70-79	0	0.00
80+	1	3.12
<b>Total</b>	<b>2</b>	<b>0.33</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	1	1.09
50-59	1	1.31
60-69	3	6.29
70-79	1	2.63
80+	1	3.12
<b>Total</b>	<b>7</b>	<b>1.17</b>


OVARY

**INCIDENCE**

Age	Female	Rate
00-29	1	0.43
30-39	4	5.13
40-49	11	11.97
50-59	21	27.55
60-69	20	41.95
70-79	17	44.68
80+	13	40.60
<b>Total</b>	<b>87</b>	<b>14.56</b>

**MORTALITY**

Age	Female	Rate
00-29	0	0.00
30-39	0	0.00
40-49	2	2.18
50-59	12	15.75
60-69	16	33.56
70-79	16	42.05
80+	11	34.36
<b>Total</b>	<b>57</b>	<b>9.54</b>



\*See Appendix 3 for frequency of incidence for each site

**MALE GENITAL SYSTEM (C60:C63)**

**INCIDENCE - TOTAL**

Age	Male	Rate
00-29	8	3.31
30-39	11	14.09
40-49	12	12.95
50-59	85	113.05
60-69	223	487.64
70-79	187	600.11
80+	101	595.52
<b>Total</b>	<b>627</b>	<b>107.78</b>

**MORTALITY - TOTAL**

Age	Male	Rate
00-29	0	0.00
30-39	1	1.28
40-49	3	3.24
50-59	4	5.32
60-69	15	32.80
70-79	63	202.18
80+	105	619.10
<b>Total</b>	<b>191</b>	<b>32.83</b>

**TESTIS**

**INCIDENCE**

Age	Male	Rate
00-29	8	3.31
30-39	11	14.09
40-49	5	5.40
50-59	3	3.99
60-69	1	2.19
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>28</b>	<b>4.81</b>

**MORTALITY**

Age	Male	Rate
00-29	0	0.00
30-39	1	1.28
40-49	1	1.08
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>2</b>	<b>0.34</b>

**PENIS**

**INCIDENCE**

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	2	6.42
80+	4	23.58
<b>Total</b>	<b>6</b>	<b>1.03</b>

**MORTALITY**

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	2	6.42
80+	1	5.90
<b>Total</b>	<b>3</b>	<b>0.52</b>

**OTHER MALE GENITAL SYSTEM**

**INCIDENCE**

Age	Male	Rate
00-69	0	0.00
70-79	1	3.21
80+	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>

**MORTALITY**

Age	Male	Rate
00-69	0	0.00
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>

**PROSTATE - IN SITU**

**INCIDENCE**

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	10	13.30
60-69	20	43.73
70-79	15	48.14
80+	1	5.90
<b>Total</b>	<b>46</b>	<b>7.91</b>

**MORTALITY**

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	0	0.00
50-59	0	0.00
60-69	0	0.00
70-79	0	0.00
80+	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>


**PROSTATE - INVASIVE**

**INCIDENCE**

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	7	7.55
50-59	82	109.06
60-69	225	492.02
70-79	186	596.90
80+	101	595.52
<b>Total</b>	<b>601</b>	<b>103.31</b>

**MORTALITY**

Age	Male	Rate
00-29	0	0.00
30-39	0	0.00
40-49	2	2.16
50-59	4	5.32
60-69	15	32.80
70-79	61	195.76
80+	104	613.21
<b>Total</b>	<b>186</b>	<b>31.97</b>



\*See Appendix 3 for frequency of incidence for each site

**URINARY SYSTEM (C64:C68)****INCIDENCE – TOTAL (INCLUDING BLADDER *IN SITU*)**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	6	7.69	0	0.00	6	3.84
40-49	16	17.27	8	8.71	24	13.00
50-59	43	57.19	21	27.55	64	42.27
60-69	68	148.70	41	86.00	109	116.69
70-79	121	388.31	51	134.03	172	248.51
80+	63	371.46	46	143.67	109	222.55
<b>Total</b>	<b>318</b>	<b>54.66</b>	<b>167</b>	<b>27.95</b>	<b>485</b>	<b>41.13</b>

**MORTALITY – TOTAL (INCLUDING BLADDER *IN SITU*)**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	5	5.40	3	3.26	8	4.33
50-59	10	13.30	3	3.94	13	8.59
60-69	16	34.99	9	18.88	25	26.76
70-79	30	96.27	13	34.16	43	62.13
80+	30	176.89	22	68.71	52	106.17
<b>Total</b>	<b>91</b>	<b>15.64</b>	<b>50</b>	<b>8.37</b>	<b>141</b>	<b>11.96</b>

**BLADDER – *IN SITU*****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	7	7.55	2	2.18	9	4.88
50-59	7	9.31	8	10.50	15	9.91
60-69	24	52.48	12	25.17	36	38.54
70-79	39	125.16	9	23.65	48	69.35
80+	28	165.09	8	24.99	36	73.50
<b>Total</b>	<b>105</b>	<b>18.05</b>	<b>39</b>	<b>6.53</b>	<b>144</b>	<b>12.21</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>




**BLADDER - INVASIVE****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	1	1.09	2	1.08
50-59	9	11.97	2	2.62	11	7.27
60-69	15	32.80	4	8.39	19	20.34
70-79	42	134.78	15	39.42	57	82.36
80+	19	112.03	18	56.22	37	75.54
<b>Total</b>	<b>86</b>	<b>14.78</b>	<b>40</b>	<b>6.69</b>	<b>126</b>	<b>10.68</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	1	1.09	2	1.08
50-59	1	1.33	0	0.00	1	0.66
60-69	7	15.31	3	6.29	10	10.71
70-79	16	51.35	8	21.02	24	34.68
80+	24	141.51	12	37.48	36	73.50
<b>Total</b>	<b>49</b>	<b>8.42</b>	<b>24</b>	<b>4.02</b>	<b>73</b>	<b>6.19</b>

**Incidence of Bladder Cancer  
by Stage\***



\*See Appendix 3 for frequency of incidence for each site


**KIDNEY AND RENAL PELVIS**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	6	7.69	0	0.00	6	3.84
40-49	8	8.63	5	5.44	13	7.04
50-59	27	35.91	11	14.43	38	25.10
60-69	29	63.42	24	50.34	53	56.74
70-79	36	115.53	26	68.33	62	89.58
80+	13	76.65	19	59.34	32	65.34
<b>Total</b>	<b>120</b>	<b>20.63</b>	<b>85</b>	<b>14.23</b>	<b>205</b>	<b>17.38</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	4	4.32	2	2.18	6	3.25
50-59	9	11.97	3	3.94	12	7.93
60-69	9	19.68	6	12.58	15	16.06
70-79	13	41.72	5	13.14	18	26.01
80+	6	35.38	10	31.23	16	32.67
<b>Total</b>	<b>41</b>	<b>7.05</b>	<b>26</b>	<b>4.35</b>	<b>67</b>	<b>5.68</b>



\*See Appendix 3 for frequency of incidence for each site

URETER

## INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	1	2.10	1	1.07
70-79	2	6.42	1	2.63	3	4.33
80+	2	11.79	0	0.00	2	4.08
<b>Total</b>	<b>4</b>	<b>0.69</b>	<b>2</b>	<b>0.33</b>	<b>6</b>	<b>0.51</b>

## MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.21	0	0.00	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>0</b>	<b>0.00</b>	<b>1</b>	<b>0.08</b>

OTHER URINARY SYSTEM

## INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	2	6.42	0	0.00	2	2.89
80+	1	5.90	1	3.12	2	4.08
<b>Total</b>	<b>3</b>	<b>0.52</b>	<b>1</b>	<b>0.17</b>	<b>4</b>	<b>0.34</b>

## MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>

**EYE (C69)****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.19	0	0.00	1	1.07
70-79	3	9.63	1	2.63	4	5.78
80+	1	5.90	3	9.37	4	8.17
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>5</b>	<b>0.84</b>	<b>10</b>	<b>0.85</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.19	0	0.00	1	1.07
70-79	1	3.21	0	0.00	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>0</b>	<b>0.00</b>	<b>2</b>	<b>0.17</b>

**BRAIN AND OTHER NERVOUS SYSTEM (C70:C72)****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	10	4.13	7	3.00	17	3.57
30-39	2	2.56	3	3.84	5	3.20
40-49	10	10.79	13	14.15	23	12.46
50-59	10	13.30	17	22.31	27	17.83
60-69	10	21.87	14	29.36	24	25.69
70-79	15	48.14	19	49.93	34	49.12
80+	6	35.38	14	43.73	20	40.83
<b>Total</b>	<b>63</b>	<b>10.83</b>	<b>87</b>	<b>14.56</b>	<b>150</b>	<b>12.72</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	3	1.24	2	0.86	5	1.05
30-39	0	0.00	0	0.00	0	0.00
40-49	4	4.32	5	5.44	9	4.88
50-59	3	3.99	14	18.37	17	11.23
60-69	7	15.31	10	20.97	17	18.20
70-79	8	25.67	10	26.28	18	26.01
80+	6	35.38	6	18.74	12	24.50
<b>Total</b>	<b>31</b>	<b>5.33</b>	<b>47</b>	<b>7.87</b>	<b>78</b>	<b>6.61</b>

**BRAIN - INVASIVE****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	8	3.31	3	1.28	11	2.31
30-39	1	1.28	1	1.28	2	1.28
40-49	6	6.47	6	6.53	12	6.50
50-59	6	7.98	6	7.87	12	7.93
60-69	6	13.12	5	10.49	11	11.78
70-79	9	28.88	10	26.28	19	27.45
80+	4	23.58	4	12.49	8	16.33
<b>Total</b>	<b>40</b>	<b>6.88</b>	<b>35</b>	<b>5.86</b>	<b>75</b>	<b>6.36</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	2	0.83	2	0.86	4	0.84
30-39	0	0.00	0	0.00	0	0.00
40-49	3	3.24	5	5.44	8	4.33
50-59	2	2.66	8	10.50	10	6.61
60-69	6	13.12	7	14.68	13	13.92
70-79	6	19.25	4	10.51	10	14.45
80+	1	5.90	2	6.25	3	6.13
<b>Total</b>	<b>20</b>	<b>3.44</b>	<b>28</b>	<b>4.69</b>	<b>48</b>	<b>4.07</b>

\*In keeping with international coding conventions, all invasive brain tumours are considered

**BRAIN - UNCERTAIN AND UNSPECIFIED****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	1	1.28	1	0.64
40-49	1	1.08	1	1.09	2	1.08
50-59	1	1.33	3	3.94	4	2.64
60-69	0	0.00	2	4.19	2	2.14
70-79	1	3.21	2	5.26	3	4.33
80+	1	5.90	2	6.25	3	6.13
<b>Total</b>	<b>5</b>	<b>0.86</b>	<b>11</b>	<b>1.84</b>	<b>16</b>	<b>1.36</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	1	1.33	5	6.56	6	3.96
60-69	1	2.19	1	2.10	2	2.14
70-79	2	6.42	5	13.14	7	10.11
80+	5	29.48	4	12.49	9	18.38
<b>Total</b>	<b>11</b>	<b>1.89</b>	<b>15</b>	<b>2.51</b>	<b>26</b>	<b>2.20</b>

**BRAIN AND NERVOUS SYSTEM – BENIGN****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	3	1.28	4	0.84
30-39	1	1.28	1	1.28	2	1.28
40-49	3	3.24	5	5.44	8	4.33
50-59	3	3.99	8	10.50	11	7.27
60-69	4	8.75	7	14.68	11	11.78
70-79	5	16.05	7	18.40	12	17.34
80+	1	5.90	8	24.99	9	18.38
<b>Total</b>	<b>18</b>	<b>3.09</b>	<b>39</b>	<b>6.53</b>	<b>57</b>	<b>4.83</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.31	1	0.66
60-69	0	0.00	1	2.10	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>2</b>	<b>0.33</b>	<b>2</b>	<b>0.17</b>

**OTHER NERVOUS SYSTEM****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>2</b>	<b>0.33</b>	<b>2</b>	<b>0.17</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	1	2.10	1	1.07
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>2</b>	<b>0.33</b>	<b>2</b>	<b>0.17</b>

**ENDOCRINE SYSTEM (C73:C75)****INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	4	1.65	11	4.71	15	3.15
30-39	1	1.28	8	10.25	9	5.77
40-49	5	5.40	10	10.88	15	8.13
50-59	5	6.65	13	17.06	18	11.89
60-69	3	6.56	5	10.49	8	8.56
70-79	1	3.21	6	15.77	7	10.11
80+	1	5.90	2	6.25	3	6.13
<b>Total</b>	<b>20</b>	<b>3.44</b>	<b>55</b>	<b>9.20</b>	<b>75</b>	<b>6.36</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	0	0.00	1	0.66
60-69	1	2.19	0	0.00	1	1.07
70-79	0	0.00	1	2.63	1	1.44
80+	1	5.90	3	9.37	4	8.17
<b>Total</b>	<b>4</b>	<b>0.69</b>	<b>4</b>	<b>0.67</b>	<b>8</b>	<b>0.68</b>

**OTHER ENDOCRINE****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	2	0.86	3	0.63
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.31	1	0.66
60-69	1	2.19	1	2.10	2	2.14
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	1	3.12	1	2.04
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>5</b>	<b>0.84</b>	<b>7</b>	<b>0.59</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	0	0.00	1	0.66
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>1</b>	<b>0.17</b>	<b>3</b>	<b>0.25</b>


**THYROID**

**INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	3	1.24	9	3.85	12	2.52
30-39	1	1.28	8	10.25	9	5.77
40-49	5	5.40	10	10.88	15	8.13
50-59	5	6.65	12	15.75	17	11.23
60-69	2	4.37	4	8.39	6	6.42
70-79	1	3.21	6	15.77	7	10.11
80+	1	5.90	1	3.12	2	4.08
<b>Total</b>	<b>18</b>	<b>3.09</b>	<b>50</b>	<b>8.37</b>	<b>68</b>	<b>5.77</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	1	2.19	0	0.00	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	1	5.90	3	9.37	4	8.17
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>3</b>	<b>0.50</b>	<b>5</b>	<b>0.42</b>



\*See Appendix 3 for frequency of incidence for each site



**LYMPHOMA (C77)****INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	13	5.37	10	4.28	23	4.84
30-39	8	10.25	4	5.13	12	7.69
40-49	15	16.19	9	9.79	24	13.00
50-59	28	37.24	17	22.31	45	29.72
60-69	32	69.98	26	54.53	58	62.09
70-79	37	118.74	29	76.21	66	95.36
80+	23	135.61	32	99.94	55	112.30
<b>Total</b>	<b>156</b>	<b>26.82</b>	<b>127</b>	<b>21.25</b>	<b>283</b>	<b>24.00</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	3	3.26	4	2.17
50-59	4	5.32	6	7.87	10	6.61
60-69	11	24.05	4	8.39	15	16.06
70-79	26	83.44	17	44.68	43	62.13
80+	15	88.44	27	84.33	42	85.75
<b>Total</b>	<b>57</b>	<b>9.80</b>	<b>58</b>	<b>9.71</b>	<b>115</b>	<b>9.75</b>

**HODGKIN DISEASE****INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	6	2.48	7	3.00	13	2.73
30-39	2	2.56	1	1.28	3	1.92
40-49	3	3.24	1	1.09	4	2.17
50-59	1	1.33	2	2.62	3	1.98
60-69	3	6.56	1	2.10	4	4.28
70-79	1	3.21	1	2.63	2	2.89
80+	1	5.90	1	3.12	2	4.08
<b>Total</b>	<b>17</b>	<b>2.92</b>	<b>14</b>	<b>2.34</b>	<b>31</b>	<b>2.63</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	1	2.63	1	1.44
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>2</b>	<b>0.33</b>	<b>2</b>	<b>0.17</b>


### NON-HODGKIN LYMPHOMA

#### INCIDENCE

Age	Male	Rate	Female	Rate	Total	Rate
00-29	7	2.89	3	1.28	10	2.10
30-39	6	7.69	3	3.84	9	5.77
40-49	12	12.95	8	8.71	20	10.84
50-59	27	35.91	15	19.68	42	27.74
60-69	29	63.42	25	52.44	54	57.81
70-79	36	115.53	28	73.59	64	92.47
80+	22	129.72	31	96.82	53	108.21
<b>Total</b>	<b>139</b>	<b>23.89</b>	<b>113</b>	<b>18.91</b>	<b>252</b>	<b>21.37</b>

#### MORTALITY

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	3	3.26	4	2.17
50-59	4	5.32	6	7.87	10	6.61
60-69	11	24.05	4	8.39	15	16.06
70-79	26	83.44	16	42.05	42	60.68
80+	15	88.44	27	84.33	42	85.75
<b>Total</b>	<b>57</b>	<b>9.80</b>	<b>56</b>	<b>9.37</b>	<b>113</b>	<b>9.58</b>



\*See Appendix 3 for frequency of incidence for each site

**MULTIPLE MYELOMA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	6	7.98	3	3.94	9	5.94
60-69	14	30.61	6	12.58	20	21.41
70-79	11	35.30	10	26.28	21	30.34
80+	8	47.17	8	24.99	16	32.67
<b>Total</b>	<b>39</b>	<b>6.70</b>	<b>28</b>	<b>4.69</b>	<b>67</b>	<b>5.68</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	2	2.18	3	1.63
50-59	1	1.33	1	1.31	2	1.32
60-69	2	4.37	3	6.29	5	5.35
70-79	12	38.51	7	18.40	19	27.45
80+	10	58.96	10	31.23	20	40.83
<b>Total</b>	<b>26</b>	<b>4.47</b>	<b>23</b>	<b>3.85</b>	<b>49</b>	<b>4.16</b>

**LEUKEMIA (C42)****INCIDENCE - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	7	2.89	8	3.42	15	3.15
30-39	3	3.84	1	1.28	4	2.56
40-49	1	1.08	5	5.44	6	3.25
50-59	9	11.97	6	7.87	15	9.91
60-69	14	30.61	16	33.56	30	32.12
70-79	23	73.81	13	34.16	36	52.01
80+	10	58.96	20	62.46	30	61.25
<b>Total</b>	<b>67</b>	<b>11.52</b>	<b>69</b>	<b>11.55</b>	<b>136</b>	<b>11.53</b>

**MORTALITY - TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	2	0.86	3	0.63
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	2	2.66	4	5.25	6	3.96
60-69	13	28.43	6	12.58	19	20.34
70-79	17	54.56	11	28.91	28	40.46
80+	16	94.34	22	68.71	38	77.59
<b>Total</b>	<b>49</b>	<b>8.42</b>	<b>45</b>	<b>7.53</b>	<b>94</b>	<b>7.97</b>

**ACUTE LYMPHOCYTIC LEUKEMIA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	5	2.07	5	2.14	10	2.10
30-39	1	1.28	0	0.00	1	0.64
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	0	0.00	1	0.66
60-69	1	2.19	0	0.00	1	1.07
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>8</b>	<b>1.38</b>	<b>5</b>	<b>0.84</b>	<b>13</b>	<b>1.10</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	2	0.86	2	0.42
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	1	3.21	1	2.63	2	2.89
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>1</b>	<b>0.17</b>	<b>3</b>	<b>0.50</b>	<b>4</b>	<b>0.34</b>

**CHRONIC LYMPHOCYTIC LEUKEMIA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	1	1.28	0	0.00	1	0.64
40-49	1	1.08	1	1.09	2	1.08
50-59	5	6.65	4	5.25	9	5.94
60-69	8	17.49	11	23.07	19	20.34
70-79	15	48.14	7	18.40	22	31.79
80+	6	35.38	13	40.60	19	38.79
<b>Total</b>	<b>36</b>	<b>6.19</b>	<b>36</b>	<b>6.02</b>	<b>72</b>	<b>6.11</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	1	1.31	2	1.32
60-69	4	8.75	1	2.10	5	5.35
70-79	2	6.42	4	10.51	6	8.67
80+	8	47.17	11	34.36	19	38.79
<b>Total</b>	<b>15</b>	<b>2.58</b>	<b>17</b>	<b>2.85</b>	<b>32</b>	<b>2.71</b>

**ACUTE MYELOID LEUKEMIA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	1	1.28	1	0.64
40-49	0	0.00	1	1.09	1	0.54
50-59	1	1.33	0	0.00	1	0.66
60-69	3	6.56	2	4.19	5	5.35
70-79	5	16.05	2	5.26	7	10.11
80+	3	17.69	3	9.37	6	12.25
<b>Total</b>	<b>13</b>	<b>2.23</b>	<b>9</b>	<b>1.51</b>	<b>22</b>	<b>1.87</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	1	1.31	1	0.66
60-69	5	10.93	3	6.29	8	8.56
70-79	7	22.46	2	5.26	9	13.00
80+	2	11.79	2	6.25	4	8.17
<b>Total</b>	<b>14</b>	<b>2.41</b>	<b>8</b>	<b>1.34</b>	<b>22</b>	<b>1.87</b>

**CHRONIC MYELOID LEUKEMIA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	2	0.86	2	0.42
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	1	1.09	1	0.54
50-59	2	2.66	1	1.31	3	1.98
60-69	1	2.19	1	2.10	2	2.14
70-79	1	3.21	1	2.63	2	2.89
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>4</b>	<b>0.69</b>	<b>6</b>	<b>1.00</b>	<b>10</b>	<b>0.85</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	1	1.33	0	0.00	1	0.66
60-69	0	0.00	2	4.19	2	2.14
70-79	1	3.21	1	2.63	2	2.89
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>2</b>	<b>0.34</b>	<b>3</b>	<b>0.50</b>	<b>5</b>	<b>0.42</b>

**OTHER LEUKEMIA****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	1	0.43	2	0.42
30-39	1	1.28	0	0.00	1	0.64
40-49	0	0.00	2	2.18	2	1.08
50-59	0	0.00	1	1.31	1	0.66
60-69	1	2.19	2	4.19	3	3.21
70-79	2	6.42	3	7.88	5	7.22
80+	1	5.90	4	12.49	5	10.21
<b>Total</b>	<b>6</b>	<b>1.03</b>	<b>13</b>	<b>2.18</b>	<b>19</b>	<b>1.61</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	2	2.62	2	1.32
60-69	4	8.75	0	0.00	4	4.28
70-79	6	19.25	3	7.88	9	13.00
80+	6	35.38	9	28.11	15	30.63
<b>Total</b>	<b>17</b>	<b>2.92</b>	<b>14</b>	<b>2.34</b>	<b>31</b>	<b>2.63</b>

**OTHER, ILL-DEFINED AND UNKNOWN (C76:C80)****INCIDENCE**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	1	1.28	2	2.56	3	1.92
40-49	9	9.71	3	3.26	12	6.50
50-59	14	18.62	10	13.12	24	15.85
60-69	22	48.11	18	37.75	40	42.82
70-79	36	115.53	34	89.35	70	101.14
80+	32	188.68	40	124.93	72	147.00
<b>Total</b>	<b>115</b>	<b>19.77</b>	<b>107</b>	<b>17.91</b>	<b>222</b>	<b>18.83</b>

**MORTALITY**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	1	0.41	0	0.00	1	0.21
30-39	0	0.00	1	1.28	1	0.64
40-49	4	4.32	3	3.26	7	3.79
50-59	9	11.97	2	2.62	11	7.27
60-69	17	37.17	16	33.56	33	35.33
70-79	33	105.90	30	78.84	63	91.02
80+	29	170.99	31	96.82	60	122.50
<b>Total</b>	<b>93</b>	<b>15.99</b>	<b>83</b>	<b>13.89</b>	<b>176</b>	<b>14.92</b>

**NEOPLASMS – UNCERTAIN AND UNSPECIFIED  
(EXCLUDING BRAIN)  
INCIDENCE – TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	8	3.31	6	2.57	14	2.94
30-39	4	5.12	7	8.97	11	7.05
40-49	11	11.87	14	15.24	25	13.55
50-59	15	19.95	14	18.37	29	19.15
60-69	24	52.48	21	44.05	45	48.18
70-79	35	112.32	25	65.70	60	86.69
80+	26	153.30	43	134.30	69	140.88
<b>Total</b>	<b>123</b>	<b>21.14</b>	<b>130</b>	<b>21.76</b>	<b>253</b>	<b>21.45</b>

**MORTALITY – TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	1	1.08	0	0.00	1	0.54
50-59	0	0.00	0	0.00	0	0.00
60-69	2	4.37	1	2.10	3	3.21
70-79	7	22.46	3	7.88	10	14.45
80+	13	76.65	18	56.22	31	63.29
<b>Total</b>	<b>23</b>	<b>3.95</b>	<b>22</b>	<b>3.68</b>	<b>45</b>	<b>3.82</b>

**OTHER *IN SITU*  
(EXCLUDING SKIN, BREAST, CERVIX, BLADDER, PROSTATE)  
INCIDENCE – TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	1	0.43	1	0.21
30-39	0	0.00	3	3.84	3	1.92
40-49	3	3.24	10	10.88	13	7.04
50-59	6	7.98	14	18.37	20	13.21
60-69	8	17.49	4	8.39	12	12.85
70-79	11	35.30	8	21.02	19	27.45
80+	10	58.96	8	24.99	18	36.75
<b>Total</b>	<b>38</b>	<b>6.53</b>	<b>48</b>	<b>8.03</b>	<b>86</b>	<b>7.29</b>

**MORTALITY – TOTAL**

Age	Male	Rate	Female	Rate	Total	Rate
00-29	0	0.00	0	0.00	0	0.00
30-39	0	0.00	0	0.00	0	0.00
40-49	0	0.00	0	0.00	0	0.00
50-59	0	0.00	0	0.00	0	0.00
60-69	0	0.00	0	0.00	0	0.00
70-79	0	0.00	0	0.00	0	0.00
80+	0	0.00	0	0.00	0	0.00
<b>Total</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>	<b>0</b>	<b>0.00</b>

**APPENDIX 1****INCIDENCE BY SITE, 2005**

Site	Male	Female	Total
Lip	33	11	44
Tongue	20	17	37
Major salivary gland	4	3	7
Floor of mouth	5	2	7
Gum and other mouth	5	10	15
Nasopharynx	4	1	5
Oropharynx	5	1	6
Hypopharynx	7	1	8
Other buccal cavity and pharynx	9	3	12
Esophagus	41	16	57
Stomach	74	47	121
Small intestine	21	15	36
Colon excluding rectum	246	253	499
Rectum and rectosigmoid	153	94	247
Anus	8	10	18
Liver	31	14	45
Gallbladder	7	12	19
Pancreas	63	57	120
Other digestive system	34	21	55
Larynx	19	5	24
Lung and bronchus	446	414	860
Other respiratory system	16	6	22
Bones and joints	10	2	12
Soft tissue (including heart)	17	15	32
Kaposi sarcoma	0	1	1
Melanomas of the skin	74	70	144
Breast	2	785	787
Cervix uteri	0	58	58
Corpus uteri	0	163	163
Uterus, NOS	0	2	2
Ovary	0	87	87
Other female genital system	0	26	26
Prostate	601	0	601
Testis	28	0	28
Penis	6	0	6
Other male genital system	1	0	1



Site	Male	Female	Total
Bladder	86	40	126
Kidney and renal pelvis	120	85	205
Ureter	4	2	6
Other urinary system	3	1	4
Eye	5	5	10
Brain	40	35	75
Other nervous system	0	2	2
Thyroid	18	50	68
Other endocrine	2	5	7
Hodgkin disease	17	14	31
Non-Hodgkin lymphoma	139	113	252
Multiple myeloma	39	28	67
Acute lymphocytic	8	5	13
Chronic lymphocytic	36	36	72
Acute myeloid	13	9	22
Chronic myeloid	4	6	10
Other leukemias	6	13	19
Other, ill defined, and unknown	115	107	222
<b>TOTAL: INVASIVE CANCERS</b>	<b>2645</b>	<b>2778</b>	<b>5423</b>
Other skin and in situ (including melanoma <i>in situ</i> )	1093	985	2078
Breast <i>in situ</i>	1	125	126
Cervix <i>in situ</i>	0	208	208
Bladder <i>in situ</i>	105	39	144
Prostate <i>in situ</i>	46	0	46
Other <i>in situ</i> (excluding skin, breast, cervix, bladder, prostate)	38	48	86
<b>TOTAL: <i>IN SITU</i> CANCERS</b>	<b>1283</b>	<b>1405</b>	<b>2688</b>
Brain uncertain and unspecified	5	11	16
Neoplasms (uncertain and unspecified – excluding brain)	123	130	253
Brain and nervous system benign	18	39	57
<b>TOTAL: OTHER CANCERS</b>	<b>146</b>	<b>180</b>	<b>326</b>
<b>TOTAL: ALL CANCERS/ALL SITES</b>	<b>4074</b>	<b>4363</b>	<b>8437</b>

## APPENDIX 2

## MORTALITY BY SITE, 2005

Site	Male	Female	Total
Lip	0	0	0
Tongue	5	5	10
Major salivary gland	3	1	4
Floor of mouth	0	0	0
Gum and other mouth	2	2	4
Nasopharynx	2	0	2
Oropharynx	1	2	3
Hypopharynx	1	0	1
Other buccal cavity and pharynx	5	1	6
Esophagus	52	19	71
Stomach	40	34	74
Small intestine	2	3	5
Colon excluding rectum	116	123	239
Rectum and rectosigmoid	42	27	69
Anus	1	2	3
Liver	27	8	35
Gallbladder	7	11	18
Pancreas	66	54	120
Other digestive system	10	16	26
Larynx	9	4	13
Lung and bronchus	367	296	663
Other respiratory system	3	2	5
Bones and joints	3	2	5
Soft tissue (including heart)	24	11	35
Kaposi sarcoma	0	1	1
Melanomas of the skin	6	11	17
Breast	3	186	189
Cervix uteri	0	14	14
Corpus uteri	0	11	11
Uterus, NOS	0	7	7
Ovary	0	57	57
Other female genital system	0	10	10
Prostate	186	0	186
Testis	2	0	2
Penis	3	0	3
Other male genital system	0	0	0

Site	Male	Female	Total
Bladder	49	24	73
Kidney and renal pelvis	41	26	67
Ureter	1	0	1
Other urinary system	0	0	0
Eye	2	0	2
Brain	20	28	48
Other nervous system	0	2	2
Thyroid	2	3	5
Other endocrine	2	1	3
Hodgkin disease	0	2	2
Non-Hodgkin lymphoma	57	56	113
Multiple myeloma	26	23	49
Acute lymphocytic	1	3	4
Chronic lymphocytic	15	17	32
Acute myeloid	14	8	22
Chronic myeloid	2	3	5
Other leukemia	17	14	31
Other ill-defined and unknown	93	83	176
<b>TOTAL: INVASIVE CANCERS</b>	<b>1330</b>	<b>1213</b>	<b>2543</b>
Other skin and <i>in situ</i> (including melanoma <i>in situ</i> )	3	3	6
Breast <i>in situ</i>	0	0	0
Cervix <i>in situ</i>	0	0	0
Bladder <i>in situ</i>	0	0	0
Prostate <i>in situ</i>	0	0	0
Other <i>in situ</i> (excluding skin, breast, cervix, bladder, prostate)	0	0	0
<b>TOTAL: <i>IN SITU</i> CANCERS</b>	<b>3</b>	<b>3</b>	<b>6</b>
Brain uncertain and unspecified	11	15	26
Neoplasms (uncertain and unspecified – excl. brain)	23	22	45
Brain and nervous system benign	0	2	2
<b>TOTAL: OTHER CANCERS</b>	<b>34</b>	<b>39</b>	<b>73</b>
<b>TOTAL: ALL CANCERS</b>	<b>1367</b>	<b>1255</b>	<b>2622</b>

**APPENDIX 3****STAGING ON SITES WITH MORE THAN 50 CASES\***

Site	Stage	%	Frequency
Esophagus	Unknown/NA	15.8	9
Esophagus	Stage I	8.8	5
Esophagus	Stage II	14.0	8
Esophagus	Stage III	21.1	12
Esophagus	Stage IV	40.4	23
<b>Total</b>			<b>57</b>
Stomach	Unknown/NA	23.1	28
Stomach	Stage I	11.6	14
Stomach	Stage II	9.9	12
Stomach	Stage III	10.7	13
Stomach	Stage IV	44.6	54
<b>Total</b>			<b>121</b>
Colon excluding rectum	Unknown/NA	8.6	43
Colon excluding rectum	Stage I	15.4	77
Colon excluding rectum	Stage II	26.1	130
Colon excluding rectum	Stage III	28.7	143
Colon excluding rectum	Stage IV	21.2	106
<b>Total</b>			<b>499</b>
Rectum and rectosigmoid	Unknown/NA	4.9	12
Rectum and rectosigmoid	Stage I	25.1	62
Rectum and rectosigmoid	Stage II	21.5	53
Rectum and rectosigmoid	Stage III	27.5	68
Rectum and rectosigmoid	Stage IV	21.1	52
<b>Total</b>			<b>247</b>
Pancreas	Unknown/NA	11.7	14
Pancreas	Stage I	9.2	11
Pancreas	Stage II	19.2	23
Pancreas	Stage III	15.0	18
Pancreas	Stage IV	45.0	54
<b>Total</b>			<b>120</b>

Site	Stage	%	Frequency
Other digestive system	Unknown/NA	43.6	24
Other digestive system	Stage I	10.9	6
Other digestive system	Stage II	14.5	8
Other digestive system	Stage III	16.4	9
Other digestive system	Stage IV	14.5	8
<b>Total</b>			<b>55</b>

Lung and bronchus	Unknown/NA	6.5	56
Lung and bronchus	Occult carcinoma	1.4	12
Lung and bronchus	Stage I	21.9	188
Lung and bronchus	Stage II	5.3	46
Lung and bronchus	Stage III	25.9	223
Lung and bronchus	Stage IV	39.0	335
<b>Total</b>			<b>860</b>

Melanomas of the skin	Unknown/NA	6.9	10
Melanomas of the skin	Stage I	66.0	95
Melanomas of the skin	Stage II	17.4	25
Melanomas of the skin	Stage III	9.0	13
Melanomas of the skin	Stage IV	0.7	1
<b>Total</b>			<b>144</b>

Breast	Unknown/NA	4.4	35
Breast	Stage I	41.3	325
Breast	Stage II	35.3	278
Breast	Stage III	12.7	100
Breast	Stage IV	6.2	49
<b>Total</b>			<b>787</b>

Cervix uteri	Unknown/NA	6.9	4
Cervix uteri	Stage I	50.0	29
Cervix uteri	Stage II	13.8	8
Cervix uteri	Stage III	20.7	12
Cervix uteri	Stage IV	8.6	5
<b>Total</b>			<b>58</b>

Corpus uteri	Unknown/NA	5.5	9
Corpus uteri	Stage I	68.7	112
Corpus uteri	Stage II	12.3	20
Corpus uteri	Stage III	8.6	14
Corpus uteri	Stage IV	4.9	8
<b>Total</b>			<b>163</b>

Site	Stage	%	Frequency
Ovary	Unknown/NA	5.7	5
Ovary	Stage I	20.7	18
Ovary	Stage II	11.5	10
Ovary	Stage III	35.6	31
Ovary	Stage IV	26.4	23
<b>Total</b>			<b>87</b>

Prostate	Unknown/NA	8.2	49
Prostate	Stage I	0.3	2
Prostate	Stage II	70.0	421
Prostate	Stage III	8.7	52
Prostate	Stage IV	12.8	77
<b>Total</b>			<b>601</b>

Bladder	Unknown/NA	12.7	16
Bladder	Stage 0	2.4	3
Bladder	Stage I	34.1	43
Bladder	Stage II	19.8	25
Bladder	Stage III	11.1	14
Bladder	Stage IV	19.8	25
<b>Total</b>			<b>126</b>

Kidney and renal pelvis	Unknown/NA	4.9	10
Kidney and renal pelvis	Stage I	56.6	116
Kidney and renal pelvis	Stage II	8.3	17
Kidney and renal pelvis	Stage III	14.6	30
Kidney and renal pelvis	Stage IV	15.6	32
<b>Total</b>			<b>205</b>

Thyroid	Unknown/NA	2.9	2
Thyroid	Stage I	57.4	39
Thyroid	Stage II	13.2	9
Thyroid	Stage III	13.2	9
Thyroid	Stage IV	13.2	9
<b>Total</b>			<b>68</b>

Non-Hodgkin lymphoma	Unknown/NA	4.0	10
Non-Hodgkin lymphoma	Stage I	35.3	89
Non-Hodgkin lymphoma	Stage II	18.7	47
Non-Hodgkin lymphoma	Stage III	16.3	41
Non-Hodgkin lymphoma	Stage IV	25.8	65
<b>Total</b>			<b>252</b>

\*In keeping with international coding conventions, all invasive brain tumours are considered unstagable.

**Appendix 4:**

**INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY**  
**3rd EDITION**

<b>Primary Site</b>	<b>Site/ Cell type</b>
<b>Buccal cavity and pharynx</b>	C00:C14
Lip	C000:C009
Tongue	C019:C029
Major salivary gland	C079:C089
Floor of mouth	C040:C049
Gum and other mouth	C030:C039, C050:C059, C060:C069
Nasopharynx	C110:C119
Oropharynx	C100:C109
Hypopharynx	C129, C130:C139
Other buccal cavity and pharynx	C090:C099, C140, C142:C148
<b>Digestive system</b>	C15:C26
Esophagus	C150:C159
Stomach	C160:C169
Small intestine	C170:C179
Colon excluding rectum	C180:C189, C260
Rectum and Rectosigmoid	C199, C209
Anus	C210:C212, C218
Liver	C220
Gallbladder	C239
Pancreas	C250:C259
Other digestive system	C240:C249, C221, C480, C481:C482,
<b>Respiratory system</b>	C30:C39
Larynx	C320:C329
Lung and bronchus	C340:C349
Other respiratory system	C300:C301, C310:C319, C384, C339, C381:C383, C388, C390:C399
<b>Bones and joints</b>	C400:C419
<b>Soft tissue (including heart)</b>	C380, C470:C479, C490:C499
<b>Skin</b>	C44
Melanomas of the skin	C440:C449 (types 8720:8790)
Other skin	C440:C449
<b>Breast</b>	C500:C509
<b>Female genital system</b>	C51:C58
Cervix uteri	C530:C539
Corpus uteri	C540:C549
Uterus, NOS	C559
Ovary	C569
Other female genital system	C529, C510:C519, C570:C589
<b>Male genital system</b>	C60:C63
Prostate	C619
Testis	C620:C629
Penis	C600:C609
Other male genital system	C630:C639

Primary Site	Site/ Cell type
<b>Urinary system</b>	C64:C68
Bladder (incl. in situ)	C670:C679
Kidney and renal pelvis	C649, C659
Ureter	C669
Other urinary system	C680:C689
<b>Eye</b>	C690:C699
<b>Brain and other nervous system</b>	C70:C72
Brain	C710:C719
Other nervous system	C710:C719 (type 953)
	C700:C709
	C720:C729
<b>Endocrine</b>	C73:C75
Thyroid	C739
Other endocrine	C379, C740:C749, C750:C759
<b>Lymphomas</b>	C77
Hodgkin disease	types 9650:9667
Non-Hodgkin lymphoma	types 9590:9596, 9670:9719, 9727:9729
	type 9823, all sites except C420, C421, C424
	type 9827, all sites except C420, C421, C424
Multiple myeloma	C421, types 9731:9732, 9734
<b>Leukemias</b>	C42
Acute lymphocytic	types 9826, 9835:9837
Chronic lymphocytic	C420(type 9823), C421 (type 9823), C421 (type 9823), C424 (type 9823)
Acute myeloid	types 9840, 9861, 9866, 9867, 9871:9874, 9895:9897, 9910, 9920
Chronic myeloid	types 9863, 9875, 9876, 9945, 9946
Other	types 9733, 9742, 9800, 9801, 9805, 9820, 9831, 9832:9834, 9860, 9870, 9891, 9930, 9931, 9940, 9948, 9963, 9964
	C420 (type 9827), C421 (type 9827), C424 (type 9827)
<b>Other, ill-defined, and unknown</b>	types 9740,9741, 9750:9758, 9760:9769, 9950:9962, 9970:9989
	C760:C768, (types 8000:9589)
	C809 (types 8000:9589)
	C420:C424 (types 8000:9589)
	C770:C779 (types 8000:9589)